Organic compounds -- part of the class 532-570 series – Organic compounds – Chalcogen in the nitrogen containing substituent
Reexamination Certificate
2006-07-18
2006-07-18
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Chalcogen in the nitrogen containing substituent
C544S127000, C544S279000, C544S333000, C544S350000, C544S362000, C546S122000, C514S233800, C514S234200, C514S249000, C514S252160, C514S253040, C514S256000, C514S264100, C514S264110, C514S300000
Reexamination Certificate
active
07078522
ABSTRACT:
A pyridopyrimidine or a naphthyridine derivative of the formula (I):wherein R1is an optionally substituted nitrogen-containing heterocyclic group, etc.; R2is H or a lower alkyl group; R3is H or an optionally substituted lower alkyl group, etc.; R4is H, a lower alkyl group, COOH, etc.; R5is a lower alkyl group which may optionally be substituted by an optionally substituted aryl etc.; one of X and Y is CH and the other is nitrogen, or both of X and Y are nitrogen; or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent PDE V inhibitory activities, and being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.
REFERENCES:
patent: 3560624 (1971-02-01), Rogers et al.
patent: 3670077 (1972-06-01), Freeman et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4229456 (1980-10-01), Bolhofer et al.
patent: 4464457 (1984-08-01), Bosse et al.
patent: 4704459 (1987-11-01), Todo et al.
patent: 4959368 (1990-09-01), Awaya et al.
patent: 5466692 (1995-11-01), Ellingboe
patent: 5525604 (1996-06-01), Lee et al.
patent: 5693652 (1997-12-01), Takase et al.
patent: 5716993 (1998-02-01), Ozaki et al.
patent: 5733914 (1998-03-01), Blankley et al.
patent: 5817670 (1998-10-01), Takayama et al.
patent: 6136810 (2000-10-01), Takayama et al.
patent: 199955977 (2000-05-01), None
patent: 2064 096 (1972-07-01), None
patent: 0 459 819 (1991-12-01), None
patent: 0 668 280 (1995-08-01), None
patent: 0722936 (1996-07-01), None
patent: 0 995 750 (2000-04-01), None
patent: 50-95273 (1975-07-01), None
patent: 54-081299 (1979-06-01), None
patent: 2000-26294 (2000-01-01), None
patent: 2000-72751 (2000-03-01), None
patent: WO 94/28902 (1994-12-01), None
patent: WO 96/16644 (1996-06-01), None
patent: WO 96/22991 (1996-08-01), None
patent: WO 98/23597 (1998-06-01), None
patent: WO 98/33798 (1998-08-01), None
patent: WO 99/09030 (1999-02-01), None
patent: WO 00/76980 (2000-12-01), None
patent: WO 01/55148 (2001-08-01), None
patent: WO 01/70741 (2001-09-01), None
patent: WO 03/062236 (2003-07-01), None
Perry, M.J. et al, Current Opinion in Chemical Biology, 1998, 2, 472-481.
Corbin JD, Francis SH., Int J Clin Pract. Jul.-Aug. 2002;56(6):453-9.
Cremers B, Bohm M., Herz. Jun. 2003;28(4):325-33.
Vermulapalli, S., et al., “Sildenafil relaxes rabbit clitoral corpus cavemsoum,” Life Sciences, vol. 67, pp. 23-29 (2000).
Watkins, C., et al., “Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastrophathy,” The Journal of Clinical Investigation, vol. 106, No. 3, pp. 373-384 (2000).
Bortolotti, M., et al., “Effects of Sildenafil on Esophageal Motility of Patients with Idiopathic Achalasia,” Gastroenterology, vol. 118, pp. 253-257 (2000).
Mule F., et al., “Tonic Inhibitory action by nitric oxide on spontaneous mechanical activity in rat proximal colon: involvement of cyclic GMP and apamin-sensitive K channels,” British Journal of Pharmacology, vol. 127, pp. 514-520 (1999).
Turner, N., et al., “Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anesthetized guinea-pig,” British Journal of Pharmacology, vol. 111, pp. 1198-1204 (1994).
Bakre M., et al., “Expression and Regulation of the cGMP-Binding, cGMP-Specific Phosphodiesterase (PDE5) in Colonic Epithelial Cells: Role in the Induction of Cellular Refractoriness to the Heat-Stable Enterotoxin Peptide,” Journal of Cellular Biochemistry, vol. 77, pp. 159-167 (2000).
Boolell, M., et al., “A new oral treatment for erectile dysfunction. A Double-blind, placebo controlled crossover study demonstrating dose response with rigiscan and efficacy with outpatient diary,” The Journal of Urology, Supplement, vol. 155, No. 5, p. 495A 739 (1996).
Terrett, N., et al., “Sildenafil (Viagra™), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction,” Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 15, pp. 1819-1824 (1996).
Ballard, S., et al., “Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase, enhances nitric oxide-dependent relaxation of rabbit corpus cavemosum,” British Journal of Pharmacology, Proceedings Supplement, vol. 118, 153P (1996).
Goldstein, I., et al., “Oral sildenafil in the treatment of erectile dysfunction,” The New England Journal of Medicine, vol. 338, No. 20, p. 1397-1404 (1998).
Goldenberg, M., “Safety and Efficacy of Sildenafil Citrate in the Treatment of Male Erectile Dysfunction,” Clinical Therapeutics, vol. 20, No. 6, pp. 1033-1048 (1998).
Morales, A., et al., “Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction,” International Journal of Impotence Research, vol. 10, No. 2, pp. 69-73 (1998).
Estrade, M., et al., “Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function,” European Journal of Pharmacology, vol. 352, pp. 157-163 (1998).
Todd, C., et al., “Sulfilimines Derived from Sulfanilamide,” Journal of American Chemical Society, vol. 65, pp. 350-355 (1943).
Grohe, K., et al., “Synthese und Reaktionen von 2,4-Dichlorpyrimidin-5-carbon-saureestem,” Liebigs Ann. Chem., pp. 1025-1035 (1973).
Chan, R., et al., “The Chemistry of an Electron-Deficient 5-Deazaflavin,8-Cyano-10-methyl-5-dezaisoalloxazine,” Journal of the American Chemical Society, vol. 99, No. 20, pp. 6721-6730 (1977).
Hirai, K., et al., “Heterocyclic Cation Systems . . . ,” J. Org. Chem., vol. 45, pp. 253-260 (1980).
Kim, D., et al., “Synthesis of New Pyrrolidine C-Nucleosides via Staudeinger-aza-Wittig Cyclization of y-Azido Ketone,” Tetrahderon Letters, 40, pp. 4825-4828 (1999).
Mertes, M., et al. “Aproaches to the Synthesis of 1-Deazauridine and 2′-Deoxy-1-deazauridine ,” J. Med. Chem., vol. 10, pp. 320-325 (1967).
van Aardt, T., et al., “Direct Synthesis of Pterocarpans via Aldol Condensation of Phenylacetates with Benzaldehydes,” Tetrahedron 55, pp. 11773-11786 (1999).
Yurugi, S., et al., “Studies on the Syntheses of N-Heterocyclic Compounds,” Ann. Rept. Takeda Res. Lab., vol. 28, pp. 1-11 (1969).
Bolhofer, W., et al., “Inhibition of Gastric Acid Secretion by 1,8-Naphthyridin-2(1H)-ones,”J. of Med. Chem.,vol. 22, No. 3, pp. 301-306 (1979).
P. L. Ferrarini et al., “Synthesis and antiplatelet activity of some 1,8-naphthyridine derivatives,” Eur J Med Chem (1994) 29, 735-741.
Hikota Masataka
Kikkawa Kohei
Koga Yuichi
Omori Kenji
Yamada Koichiro
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
McKenzie Thomas C.
Tanabe Seiyaku Co. Ltd.
LandOfFree
Pyridopyrimidine or naphthyridine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridopyrimidine or naphthyridine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridopyrimidine or naphthyridine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3600685